FBT Performance — First Trust NYSE Arca Biotechnology Index Fund
Data updated: 2026-08-21
FBT returned +20.36% year to date and +53.94% over one year to Jun 2026. Annualised returns are +17.81% over 3 years and +7.64% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $164, against $138 for the category, and to $154 over one year, against $137. Volatility over the past three years was 18.70% a year. In the 12 months to Jun 2026 the fund took in a net $1.1B, and assets reached $2.81B.
FBT Growth of $100
What $100 invested in First Trust NYSE Arca Biotechnology Index Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | FBT | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $154 | $137 |
| 3 years (Jul 2023 – Jun 2026) | $164 | $138 |
| 5 years (Jul 2021 – Jun 2026) | $145 | $121 |
| Since data start (Jul 2019 – Jun 2026) | $177 | $182 |
FBT Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +20.36% |
| 1 year | +53.94% |
| 3 years (annualised) | +17.81% |
| 5 years (annualised) | +7.64% |
FBT Annual Returns
Calendar-year total returns of First Trust NYSE Arca Biotechnology Index Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +20.36% |
| 2025 | +24.07% |
| 2024 | +5.75% |
| 2023 | +2.27% |
| 2022 | −4.60% |
| 2021 | −3.63% |
| 2020 | +12.91% |
| 2019 (Jul–Dec) | +5.71% |
FBT Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +3.3% | −1.8% | −3.8% | +1.9% | +8.8% | +11.2% | — | — | — | — | — | — |
| 2025 | +9.0% | −3.1% | −2.9% | −4.4% | −0.9% | −0.1% | +1.9% | +5.0% | +4.4% | +7.3% | +11.2% | −4.0% |
| 2024 | −5.8% | +1.5% | +1.9% | −6.5% | +3.7% | +3.0% | +8.5% | +2.3% | +0.9% | −1.5% | +2.8% | −4.2% |
| 2023 | +5.9% | −6.0% | +0.9% | −0.9% | −0.4% | −0.3% | +1.9% | −0.7% | −5.2% | −9.2% | +6.5% | +11.7% |
| 2022 | −8.1% | −1.6% | +1.8% | −8.9% | −0.7% | +0.5% | +3.4% | −2.8% | −3.1% | +8.6% | +8.5% | −0.7% |
| 2021 | +4.2% | −4.0% | −4.6% | +2.4% | −0.7% | +5.9% | −2.6% | +3.4% | −4.5% | −0.1% | −5.5% | +3.3% |
| 2020 | −4.7% | +1.2% | −8.6% | +15.5% | +9.0% | +1.4% | −1.1% | −3.2% | −2.1% | −2.8% | +5.6% | +4.2% |
| 2019 | — | — | — | — | — | — | −2.8% | −5.8% | −3.9% | +4.8% | +13.1% | +1.4% |
FBT Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 18.70%
- 3-year Sharpe ratio: 0.71 (vs 4.5% risk-free rate)
- Best month: +11.65% (Dec 2023)
- Worst month: −9.18% (Oct 2023)
FBT Fund Flows
Monthly money in and out of First Trust NYSE Arca Biotechnology Index Fund, from SEC Form N-PORT.
- 12-month net flow: $1.1B
- 12-month gross sales (incl. reinvestments): $1.4B
- Sales ÷ redemptions: 5.04×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $24.5M | $74.3M | −$49.8M |
| May 2026 | $73.7M | $11.1M | $62.6M |
| Apr 2026 | $10.0M | $20.3M | −$10.2M |
| Mar 2026 | $30.8M | $49.3M | −$18.5M |
| Feb 2026 | $41.9M | $20.9M | $21.0M |
| Jan 2026 | $1.1B | $54.3M | $1.1B |
| Dec 2025 | $42.1M | $10.4M | $31.7M |
| Nov 2025 | $49.9M | $0 | $49.9M |
| Oct 2025 | $0 | $9.4M | −$9.4M |
| Sep 2025 | $0 | $0 | $0 |
| Aug 2025 | $0 | $17.4M | −$17.4M |
| Jul 2025 | $0 | $8.2M | −$8.2M |
FBT Assets Under Management
Net assets of First Trust NYSE Arca Biotechnology Index Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $2.81B |
| 2026-03-31 | $2.27B |
| 2025-12-31 | $1.33B |
| 2025-09-30 | $1.10B |
| 2025-06-30 | $1.01B |
| 2025-03-31 | $1.11B |
| 2024-12-31 | $1.11B |
| 2024-09-30 | $1.21B |
| 2024-06-30 | $1.11B |
| 2024-03-31 | $1.17B |
| 2023-12-31 | $1.29B |
| 2023-09-29 | $1.26B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.